Cyclotron production and quality control of “high specific activity' radionuclides in “no-carrier-added' form for radioanalytical applications in the life sciences

Applications of Fluorine in Medicinal Chemistry

“…The specific activity (SA) for the “in-target” protocol is in the range of 27 mCi/mmol (1 GBq/mmol), which is significantly lower than the specific activities reached using [ 18 F]-fluoride which can be as high as 150 Ci/μmol (5500 GBq/μmol) . SA is defined as the amount of isolated activity of a purified [ 18 F] PET tracer divided by the mass (or molar amount) of the total sum of all radioactive and nonradioactive species present within that isolated PET tracer . When PET imaging studies are performed, the amount of radioactivity to be administered is fixed within a range to ensure high quality images are obtained.…”

Excitation functions and yields for cyclotron production of radiorheniumvianatW(p,ߙxn)181-186gRe nuclear reactions and tests on the production of186gRe using enriched186W

“…[1][2][3], widely used in nuclear medicine as radiodiagnostic and radiotherapeutic powerful tools when labelled to proper molecules [4]. These radioactive tracers are commonly, but not properly named radiopharmaceuticals, because no pharmacological effects are expected, due to the very small molar amount administered to the patient.…”

27 Radiochemistry and radiopharmaceuticals

“…Cyclotron production of radionuclides with very high specific activities has been reviewed 3 as has the still burgeoning field of the use of ion-exchangers 15 in chromatographic radionuclide generators.…”

“…There have been many reviews on various aspects of the synthesis of radiolabelled compounds for imaging and therapy as well as their application. Amongst these are a review on the use of labelled oligonucleotides for imaging, 3 a review on fluorinated nucleosides and agents for imaging gene expression (in French), 4 a well referenced review on the role of coordination chemistry in the development of targets for specific radiopharmaceuticals, 5 a review on prospects for clinically useful positron emitting radiopharmaceuticals beyond 2-fluoro-2-deoxyglucose (FDG), 6 several reviews discussing peptide based radiopharmaceuticals, [7][8][9][10] a review on the use of radiolabelled compounds for the diagnosis of infection and inflammatory disease 11 and a review on the development of radiolabelled tracers for imaging tumour anti-angiogenesis. 12 The agents being developed to image angiogenesis can also be used to evaluate anti-angiogenic therapies.…”